Kera Capital Partners Inc. Takes $822,000 Position in Astrazeneca Plc $AZN

Kera Capital Partners Inc. bought a new position in Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,684 shares of the company’s stock, valued at approximately $822,000.

Several other institutional investors also recently modified their holdings of the business. MV Capital Management Inc. purchased a new stake in shares of Astrazeneca in the 4th quarter worth approximately $26,000. Lloyd Advisory Services LLC. purchased a new position in Astrazeneca during the fourth quarter valued at $35,000. Basepoint Wealth LLC bought a new stake in Astrazeneca in the fourth quarter worth $44,000. Acumen Wealth Advisors LLC bought a new stake in Astrazeneca in the fourth quarter worth $47,000. Finally, Nemes Rush Group LLC boosted its holdings in Astrazeneca by 162.1% in the fourth quarter. Nemes Rush Group LLC now owns 270 shares of the company’s stock worth $47,000 after acquiring an additional 167 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

AZN has been the subject of several analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of Astrazeneca in a report on Monday, June 8th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Finally, TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Trading Down 1.7%

Shares of NYSE:AZN opened at $174.87 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a market cap of $271.20 billion, a P/E ratio of 26.26, a PEG ratio of 1.55 and a beta of 0.25. The stock’s fifty day moving average price is $187.22 and its 200-day moving average price is $186.24.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Sell-side analysts expect that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.